Elafibranor, a PPAR-α and PPAR-δ activator, led to resolution of NASH, improved insulin resistance and serum lipid levels, but also caused an increase in creatinine levels [139,140]. Here, PPARD is linked to metabolic dysfunction-associated steatohepatitis.